AR and metastatic neoplasm: All patients with metastatic disease now have access to a combination treatment associating androgen deprivation therapy (ADT, e.g., goserelin, leuprorelin or triptorelin) with either docetaxel, abiraterone acetate or androgen receptor (AR) antagonists such as enzalutamide, apalutamide or darolutamide [2,3].